Brompton Enhanced Multi Asset Income ETF (BMAX) Quote

BTW: Yescarta
The FDA updated the approval for Yescarta (axicabtagene ciloleucel) in April 2022 to allow it to be used as a second-line treatment. This was the first time a CAR T-cell therapy was approved for use as a second-line treatment.

In other words, not SOC.

10K 0.002
10K 0.0004

TGRP GETTING SMOKED...WARNED

>>> Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium


PR Newswire

September 24, 2024


https://finance.yahoo.com/n

Looks like they recently terminated their offering...

RAADR, INC. (Form: 1-Z, Received: 09/17/2024 12:39:42) (otcmarkets.com)


certifies that it meets all of the conditions for termination of Regulation A reporting specified in

$XXII BIG NEWS: $XXII 22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume
CMO customer adds to previously announced cigarette export business with combined volume significantly adding to profitability

Mocksville, North Carolina--(Newsfile Corp. -

$XXII BIG NEWS: $XXII 22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume
CMO customer adds to previously announced cigarette export business with combined volume significantly adding to profitability

Mocksville, North Carolina--(Newsfile Corp. -

FAAS 10 day hourly
https://investorshub.advfn.com/uimage/uploads/2024/9/25/gwcrrIMG_2125.gif

What did hkd do? What's your price target for xhg? Thanks

nice volume

Go big or go home

What are your expectations?

Regarding financials, don't expect any until the next annual report is due - BIEL no longer files quarterly reports. Regarding news - there likely isn't anything KW is willing or able to report. She has stated when she has news that she can release she

Ill take a look around and hunt some down.

Claims that it's hidden and the TA doesn't even know about it yet. He also claims inside information of a 1 for 2000 reverse split coming. Been claiming these things for at least a year now.

Btw, I hope I'm wrong in this one because I thought their T product was on the right track. But it feels to me like everything is being gutted.

They must've reconsidered... lololol

Some here sound as tho they're
HYPNOTIZED

RNAZ On the nasdaq big time brother,

I don't imagine it will hit a dollar off the bat from what I have read from other posts on here, maybe a couple years from now as the merging business grows and gains more attention. I think the realistic figures I have seen if I receall correctly are around like 0.25 per share, which is still a ton

Good question, but I doubt it. If you follow the cycle, he usually gets issued his shares towards the bottom of the price fall off, and some time before announcing a SH meeting via 14A. Those shares are used to control the vote and aren't sold until after the RS. It's a continuous cycle. If you reme

With Chandra's evasive and dispassionate answers today on 'X', I'm inclined to agree on all points. He could actually be uniting all shareholders, patient and incensed right now, for a huge Adnexus launch, but so far nothing that even remotely resembles true leadership or shareholder interests from

OUCH...YOU WERE WARNE ABOUT THE TOP RINSE...RUG PULL WITH NO WEEKLY TREND

But she doesn't lie more than the Orange Felon so, as usual, no f'ing point for you.

We are all amariaddicts. Otherwise why in the world would any of us still be here. Except of course our beloved paid bashers and those bitter souls who sold for epic losses.

In 2023, several cancer and oncology drugs were approved by the FDA. Here are some notable examples:

1. **Epkinly (epcoritamab-bysp)**
Approved on May 19, 2023, Epkinly is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymp

Good job trading 101!